A study by Yale University has found a Silent Allosteric Modulation (SAM) drug named BMS-984923to be capable of recovering neuronal synapse losses in mice models for Alzheimer’s disease (AD), creating hope for human dementia patients affected by AD.
Synapse [neuronal connection] loss “disrupt neural networks and cause cognitive decline seen in Alzheimer’s,” said Dr. Stephen Strittmatter, co-author of the study and founder of the company that holds the license to the drug.
Synapses are the gaps or connections between neurons, working as connection points between neurons.
Most neurons communicate by passing chemical or electrical messages from the end of the nerve past the synapse to the following neuron, forming neural networks that allow neurons across the brain and body to communicate….